MA32727B1 - Pyrazolylaminopyridines au titre d'inhibiteurs de fak - Google Patents

Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Info

Publication number
MA32727B1
MA32727B1 MA33791A MA33791A MA32727B1 MA 32727 B1 MA32727 B1 MA 32727B1 MA 33791 A MA33791 A MA 33791A MA 33791 A MA33791 A MA 33791A MA 32727 B1 MA32727 B1 MA 32727B1
Authority
MA
Morocco
Prior art keywords
pyrazolylaminoperidine
fak inhibitors
present
fak
inhibitors
Prior art date
Application number
MA33791A
Other languages
Arabic (ar)
English (en)
Inventor
Hong Lin
Jiri Kasparec
Jerry Leroy Adams
Thomas H Faitg
Neil W Johnson
Mark Mellinger
Xin Peng
Ren Xie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32727(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA32727B1 publication Critical patent/MA32727B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU L'UN DE SES SELS DE QUALITÉ PHARMACEUTIQUE, OÙ R1, R2, R3, R11, R12, R13, Q, Z ET P SONT TELS QUE DÉCRITS DANS LA PRÉSENTE INVENTION. LES COMPOSÉS SELON LA PRÉSENTE INVENTION PEUVENT ÊTRE EMPLOYÉS DANS LE TRAITEMENT DE CANCERS.
MA33791A 2008-10-27 2011-04-22 Pyrazolylaminopyridines au titre d'inhibiteurs de fak MA32727B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15
PCT/US2009/062163 WO2010062578A1 (fr) 2008-10-27 2009-10-27 Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Publications (1)

Publication Number Publication Date
MA32727B1 true MA32727B1 (fr) 2011-10-02

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33791A MA32727B1 (fr) 2008-10-27 2011-04-22 Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Country Status (35)

Country Link
US (6) US20100113475A1 (fr)
EP (1) EP2421537B1 (fr)
JP (1) JP5642689B2 (fr)
KR (1) KR101512217B1 (fr)
CN (1) CN102264371B (fr)
AR (1) AR073993A1 (fr)
AU (1) AU2009320144B2 (fr)
BR (1) BRPI0920053B8 (fr)
CA (1) CA2741760C (fr)
CL (1) CL2011000933A1 (fr)
CO (1) CO6361929A2 (fr)
CR (1) CR20110264A (fr)
CY (1) CY1116399T1 (fr)
DK (1) DK2421537T3 (fr)
DO (1) DOP2011000113A (fr)
EA (1) EA021927B1 (fr)
ES (1) ES2539835T3 (fr)
HR (1) HRP20150531T1 (fr)
IL (1) IL212444A (fr)
JO (1) JO3067B1 (fr)
MA (1) MA32727B1 (fr)
MX (1) MX2011004369A (fr)
MY (1) MY161890A (fr)
NZ (1) NZ592477A (fr)
PE (1) PE20110941A1 (fr)
PL (1) PL2421537T3 (fr)
PT (1) PT2421537E (fr)
RS (1) RS54045B1 (fr)
SG (1) SG195608A1 (fr)
SI (1) SI2421537T1 (fr)
SM (1) SMT201500157B (fr)
TW (1) TWI454467B (fr)
UY (1) UY32200A (fr)
WO (1) WO2010062578A1 (fr)
ZA (1) ZA201102892B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations
WO2012110773A1 (fr) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Inhibiteurs de fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
CA2840211A1 (fr) * 2011-06-28 2013-01-03 Glaxosmithkline Intellectual Property (No.2) Limited Procede d'administration et de traitement
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (fr) * 2017-12-15 2019-06-20 National University Of Singapore Agents thérapeutiques ciblant une kinase d'adhésion focale pour le traitement du glaucome et de la fibrose
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
CA3109617A1 (fr) 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degradation de fak ou fak et alk par conjugaison d'inhibiteurs de fak et d'alk avec des ligands de ligase e3 et procedes d'utilisation
CN111377871B (zh) * 2018-12-27 2021-03-19 海创药业股份有限公司 一种fak抑制剂及其联合用药物
JP2022525186A (ja) 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｄ転写因子新規小分子阻害剤
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
CN119499253A (zh) * 2024-11-15 2025-02-25 贵州医科大学 一种化合物在抑制Aurora和JAK激酶家族活性及在几种肿瘤治疗方面的应用
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
DE69928411D1 (de) * 1998-09-08 2005-12-22 Agouron Pharma Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (fr) * 2005-07-15 2007-01-24 4Sc Ag Analogues de 2-arylbenzothiazole utiles comme agents anticancereux
EP2134689B1 (fr) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibiteurs de kinase d'adhérence focale
WO2009105498A1 (fr) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines utilisées comme inhibiteurs de fak
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物

Also Published As

Publication number Publication date
KR20110080172A (ko) 2011-07-12
IL212444A0 (en) 2011-06-30
HRP20150531T1 (hr) 2015-06-19
PL2421537T3 (pl) 2015-08-31
PE20110941A1 (es) 2012-02-08
JP2012506876A (ja) 2012-03-22
KR101512217B1 (ko) 2015-04-15
SI2421537T1 (sl) 2015-06-30
BRPI0920053A2 (pt) 2015-12-15
MX2011004369A (es) 2011-05-25
EA201170617A1 (ru) 2011-12-30
EA021927B1 (ru) 2015-09-30
JP5642689B2 (ja) 2014-12-17
JO3067B1 (ar) 2017-03-15
ZA201102892B (en) 2012-02-29
CL2011000933A1 (es) 2011-10-21
HK1161680A1 (en) 2012-08-03
TW201028394A (en) 2010-08-01
US20110269774A1 (en) 2011-11-03
CR20110264A (es) 2011-10-04
US20100113475A1 (en) 2010-05-06
WO2010062578A1 (fr) 2010-06-03
US20160095841A1 (en) 2016-04-07
NZ592477A (en) 2013-01-25
US20110207743A1 (en) 2011-08-25
CN102264371B (zh) 2013-10-02
CN102264371A (zh) 2011-11-30
CA2741760C (fr) 2016-02-23
EP2421537B1 (fr) 2015-04-08
DK2421537T3 (da) 2015-06-22
UY32200A (es) 2010-05-31
BRPI0920053B1 (pt) 2019-11-26
EP2421537A4 (fr) 2012-06-13
AR073993A1 (es) 2010-12-15
EP2421537A1 (fr) 2012-02-29
ES2539835T3 (es) 2015-07-06
CY1116399T1 (el) 2017-02-08
US9012479B2 (en) 2015-04-21
DOP2011000113A (es) 2011-07-15
TWI454467B (zh) 2014-10-01
CO6361929A2 (es) 2012-01-20
SMT201500157B (it) 2015-09-07
SG195608A1 (en) 2013-12-30
MY161890A (en) 2017-05-15
AU2009320144B2 (en) 2013-11-21
RS54045B1 (sr) 2015-10-30
CA2741760A1 (fr) 2010-06-03
BRPI0920053B8 (pt) 2021-05-25
AU2009320144A1 (en) 2010-06-03
IL212444A (en) 2015-11-30
PT2421537E (pt) 2015-07-03
US9446034B2 (en) 2016-09-20
US20150265589A1 (en) 2015-09-24
US20140107131A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA30652B1 (fr) Composes organiques
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA29926B1 (fr) Derives de pyrazine
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
EA201170772A1 (ru) Органические соединения
MA31466B1 (fr) Derives de benzimidazole
TN2009000450A1 (fr) Derives de pyridine
JO2870B1 (en) Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA33642B1 (fr) Composés chimiques